Evaluation of inflammatory parameters and ferritin as prognostic factors in non-small cell lung cancer patients receiving nivolumab immunotherapy
Authors:
- 13 February 2026
- journal article
- Published by Taylor & Francis in Biomarkers
- Vol. 31 (2) , 91-100
Abstract
AimInflammation and immune dysfunction significantly impact cancer progression and treatment responses. This retrospective study investigated inflammatory parameters and ferritin in predicting immunotherapy response in non-small cell lung cancer (NSCLC) patients.MethodsThe study included 199 patients with NSCLC who received nivolumab between 2018 and 2024 at five medical centers. Various inflammatory markers were also evaluated. Ferritin levels at diagnosis and pretreatment were also evaluated.ResultsROC curve analyses showed ferritin delta had high prognostic performance for PFS and OS, with AUC values of 0.70 and 0.73. PIV and PNI were significantly associated with PFS and OS. In Kaplan-Meier analyses, PNI was the most consistent prognostic factor. Low PNI (≤43.5) significantly associated with shorter OS (5.0 vs. 15.0 months, p = 0.001) and shorter PFS (4.0 vs. 8.0 months, p = 0.002). High mGPS (score 2) and elevated PIV showed significant prognostic value. In multivariate Cox regression, PNI demonstrated independent prognostic significance. Objective response rate was the strongest prognostic factor for PFS (HR = 0.188, 95%CI: 0.114-0.309, p < 0.001).ConclusionThese findings highlight the prognostic value of inflammatory and nutritional markers in patients with NSCLC receiving immunotherapy. PNI demonstrated the most consistent prognostic value across multiple analytical approaches and maintained significance in the multivariate analysis.Keywords
This publication has 46 references indexed in Scilit:
- Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?Critical Reviews in Oncology/Hematology, 2022
- The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis2021
- Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitorsCancer Immunology, Immunotherapy, 2020
- Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAdvances in Therapy, 2020
- Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysisCancer Medicine, 2019
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancerGastric Cancer, 2019
- Tumor Recurrence After Complete Resection for Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2012
- Immunity, Inflammation, and CancerCell, 2010
- Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?Current Opinion in Immunology, 2007
- Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionCancer Immunology, Immunotherapy, 2006